- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 2141808 [Title] => Philippines wins global science competition [Summary] => The Philippines won the first-ever Global Innovation through Science and Technology Catalyst Pitch competition given by the US Department of State with its Philippine-based startup Galansiyang, placing first in two categories. [DatePublished] => 2021-11-17 00:00:00 [ColumnID] => 0 [Focus] => 1 [AuthorID] => 1804865 [AuthorName] => Pia Lee-Brago [SectionName] => Headlines [SectionUrl] => headlines [URL] => ) [1] => Array ( [ArticleID] => 700713 [Title] => Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't [Summary] =>Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
[DatePublished] => 2011-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 698526 [Title] => Novartis partners with NKTI to enhance mg't of gastrointestinal stromal tumor [Summary] =>Research-based health care company Novartis has partnered with the National Kidney and Transplant Institute (NKTI) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
[DatePublished] => 2011-06-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
GIST
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 2141808 [Title] => Philippines wins global science competition [Summary] => The Philippines won the first-ever Global Innovation through Science and Technology Catalyst Pitch competition given by the US Department of State with its Philippine-based startup Galansiyang, placing first in two categories. [DatePublished] => 2021-11-17 00:00:00 [ColumnID] => 0 [Focus] => 1 [AuthorID] => 1804865 [AuthorName] => Pia Lee-Brago [SectionName] => Headlines [SectionUrl] => headlines [URL] => ) [1] => Array ( [ArticleID] => 700713 [Title] => Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't [Summary] =>Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
[DatePublished] => 2011-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 698526 [Title] => Novartis partners with NKTI to enhance mg't of gastrointestinal stromal tumor [Summary] =>Research-based health care company Novartis has partnered with the National Kidney and Transplant Institute (NKTI) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
[DatePublished] => 2011-06-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 464588 [Title] => Reducing risk of cancer returning in patients [Summary] =>MANILA, Philippines – Data published in the online edition of the Lancet show that imatinib, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
[DatePublished] => 2009-05-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2/LVM - 14 16
SUERTRES - 8 3 2
6D Lotto - 9 0 3 0
6/45 Lotto - 41 44 23 3 17 5
P94,470,811.00
6/58 Ultra Lotto - 46 19 11 40 41 16
P228,127,654.00
- 12:00 am